Status:

RECRUITING

Biomarkers for Risk Stratification in Lung Cancer

Lead Sponsor:

University of California, San Francisco

Collaborating Sponsors:

Northern California Institute of Research and Education

Guardant Health, Inc.

Conditions:

Nodule Solitary Pulmonary

Non-small Cell Lung Cancer

Eligibility:

All Genders

40+ years

Brief Summary

This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Cen...

Detailed Description

Study objectives and statistical approaches to achieve those objectives are determined at the level of the populations described below: Population 1: Sensitivity and Specificity Thresholding. In thi...

Eligibility Criteria

Inclusion

  • Age ≥ 40 years
  • Ability to understand and provide written informed consent
  • Willingness to comply with study protocols and provide blood samples.
  • Willingness to complete 3-year clinical follow up

Exclusion

  • Active non-cutaneous malignancy within the past 5 years as per medical record or patient report.
  • Exclusion criteria for possible follow-up visit blood draw:
  • Anemia - measured by hematocrit level of less than 30%, measured after the first blood draw.
  • Malnourishment - determined by BMI less than 19. If subject has BMI greater or equal to 19, but has a history of malnourishment, study staff will measure albumin level of subject's blood after initial blood draw. Albumin level must be greater than 2.5 mg per deciliter, or subject will be excluded.
  • Severe Chronic Obstructive Pulmonary Disease (COPD) - defined by Gold Stage IV.
  • Unstable heart conditions - defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy, or history of complications because of previous blood donation.
  • Liver cirrhosis.

Key Trial Info

Start Date :

December 17 2017

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

590 Patients enrolled

Trial Details

Trial ID

NCT03774758

Start Date

December 17 2017

End Date

December 31 2025

Last Update

March 20 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Zuckerberg San Francisco General Hospital and Trauma Center

San Francisco, California, United States, 94110

2

San Francisco VA Medical Center

San Francisco, California, United States, 94121

3

University of California, San Francisco

San Francisco, California, United States, 94122